Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Nature Reviews Drug Discovery 18, 731-732 (2019)
M.J.C. is director of the Centre for Patient Reported Outcome Research at the University of Birmingham and receives funding from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre at the University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support and the Patient-Centered Outcomes Research Institute (PCORI). D.J.O. is a UK government employee of the Medicines and Healthcare products Regulatory Agency (MHRA), UK. E.M.B. is an employee of the University of North Carolina, receives research funding from the US National Cancer Institute and PCORI, is on the board of the American Society of Clinical Oncology, is an associate editor for JAMA and is a scientific advisor to Carevive Systems, Sivan and Self Care Catalysts.
This publication reflects the views of the individual authors and should not be construed to represent official views or policies of the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Health Service, the National Institute for Health Research, the Department of Health or the UK government. All authors are members of the SPIRIT-PRO, SISAQOL and PROTEUS consortia.
Engel, P. et al. Lessons learned on the design and the conduct of post-authorization safety studies: review of 3 years of PRAC oversight. Br. J. Clin. Pharmacol. 83, 884–893 (2016).
Kluetz, P. G. et al. Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol. 19, e267–e274 (2018).
Calvert, M. et al. Maximising the impact of patient reported outcome assessment for patients and society. BMJ 364, k5267 (2019).
Kyte, D. et al. Reflections on the national patient-reported outcome measures (PROMs) programme: where do we go from here? J. R. Soc. Med. 109, 441–445 (2016).
Calvert, M. et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA 319, 483–494 (2018).
M.J.C. has received personal fees from Astellas Pharma, Takeda, Glaukos and Merck outside the submitted work.